Functional and clinical aspects of the myelomonocyte protein calprotectin

Journal of Clinical Pathology - Molecular Pathology

Volumn 50, Issue 3, 1997, Pages 113-123

  Johne, B ^a   Fagerhol, M K ^b   Lyberg, T ^c   Prydz, H ^c   Brandtzaeg P ^c   Naess Andresen, C F ^b   Dale, I ^b  

^a ALTANA PHARMA AG   (Germany)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CALCIUM BINDING PROTEIN; CALPROTECTIN; PROTEIN S 100;

ACUTE PHASE RESPONSE; BONE MARROW CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSKELETON; CYTOTOXICITY; DISEASE MARKER; HOST RESISTANCE; HUMAN; HUMAN CELL; INFLAMMATION; MONOCYTE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030663041     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.50.3.113     Document Type: Review

References (142)

1. Fagerhol MK, Anderson KB, Naess-Andresen CF, Brandtzæg P, Dale I. Calprotectin (the L1 leukocyte orotein). In: Smith VL, Dedman JR, eds. Stimulus response coupling: the role of intracellular calcium-binding proteins. Boca Raton: CRC: Press Inc, 1990:187-210.
2. Fagerhol MK. Nomenclature for proteins; is calprotectin a proper name tor the elusive myelomonocytic protein? J Clin Pathol: Mol Pathol 1996;49:M74-9.
3. Brandtzæg P, Dale I, Gabrielsen TO. The leukocyte protein L1 (calprotectin): usefulness as an immunohistochemical marker antigen and putative biological function. Histopathology 1992;21:191-6.
4. Brandtæg P, Gabrielsen T-Ø, Dale I, Müller F, Steinbakk M, Fagerhol MK. The leukocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Adv Exp Med Biol 1995;371:201-6.
5. Sorg C. The calcium binding proteins MRP8 and MRP14 in acute and chronic inflammation. Behringer Inst Mitt 1992;91:126-37.
6. Brun JG, Ulvestad E, Fagerhol MK, Jonsson R. Effects of human calprotectin (L1) on in vitro immunoglobulin synthesis. Scand J Immunol 1994;40:675-80.
7. McNamara MP, Weissner JH, Collins-Lech C, Hahn JH, Sohnle PG. Neutrophil death as a defence mechanism against Candida albicans infections. Lancet 1988;ii:1163-5.
8. Steinbakk M, Naess-Andresen C-F, Lingaas E, Dale I, Brandtzæg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990;336:763-5.
9. Hahn BL, Sohnle PG. Resistance of zinc-supplemented Candida albicans cells to the growth inhibitory effect of calprotectin. J Infect Dis 1995;171:1289-94.
10. Yui S, Mikami M, Yamazaki M. Purification and characterization of the cytotoxic factor in rat peritoneal exudate cells: its identification as the calcium binding protein complex, calprotectin. J Leukocyte Biol 1995;58:307-16.
11. Yui S, Mikami M, Yamazaki M. Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells. J Leukocyte Biol 1995;58:650-8.
12. Berntzen HB, Endresen GK, Fagerhol MK, Spiechowicz J, Mowinckel P. Calprotectin (the L1 protein) during surgery in patients with rheumatoid arthritis. Scand J Clin Lab Invest 1991;51:643-50.
13. Berntzen HB, Fagerhol MK, Østensen M, Mowinckel P, Hryeraal HM. The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J Rheumatol 1991;18:1338.
14. Berntzen HB, Ölmez Ü, Fagerhol MK, Munthe E. The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991;20:74-82.
15. Sander J, Fagerhol MK, Bakken JS, Dale I. Plasma levels of the leukocyte L1 protein in febrile conditions: relation to aetiology, number of leukocytes in blood, blood sedimentation reaction and C-reactive protein. Scand J Clin Lab Invest 1984;44:357-62.
16. Dale I, Brandtzæg P. Expression of the epithelial L1 antigen as immunohistochemical marker of squamous cell carcinoma of the lung. Histopathology 1989;14:493-502.
17. Røseth AG, Kristinsson J, Fagerhol MK, Schønsby H, Aadland E, Nygaard K, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073-6.
18. Dunlop O, Bruun JN, Myrvang B, Fagerhol MK. Calprotectin in cerebrospinal fluid of the HIV infected: a diagnostic marker of opportunistic central nervous system infection? Scand J Infect. Dis 1991;23:687-9.
19. Røseth AG, Fagerhol MK, Aadland E, Schønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27: 793-8.
20. Brandtzæg P, Dale I, Fagerhol MK. Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. 1. Comparison with other leukocyte markers by paired immunofluorescence and immunoenzyme staining. Am J Clin Pathol 1987;87:681-99.
21. Miyasaki KT. The Neutrophil: mechanisms of controlling periodontal bacteria. J Periodontol 1991;62:761-74.
22. Brun JG, Haga H-J, Boe E, Kallay I, Lekven C, Berntzen HB, et al. Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity. J Rheumatol 1992;19:859-62.
23. Brandtzæg P, Kierulf P. Endotoxin and meningococcemia. Intravascular inflammation induced by native endotoxin in man. In: Ryan JL, Morrison DC, eds. Bacterial endotoxic lipopolysaccharides. Vol II. Immunopharmacology and pathophysiology. Boca Raton: CRC Press, 1992:327-46.
24. Hammer HB, Kvien TK, Glennas A, Melby K. A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol 1995;13:59-64.
25. Kjeldsen-Kragh J, Mellbye OJ, Haugen M, Mollnes TE, Hammer HB, Sioud M, et al. Changes in laboratory variables in rheumatoid arthritis patients during a trial of fasting and one-year vegetarian diet. Scand J Rheumatol 1995;24:85-93.
26. Soderquist B, Sundqvist KG, Jones I, Holmberg H, Vikerfors T. Interleukin-6, C-reactive protein, lactoferrin and white blood cell count in patients with S aureus septicemia. Scand J Infect Dis 1995;27:375-80.
27. Freemont P, Hogg N, Edgeworth J. Sequence identity. Nature 1989;339:516.
28. Johne B, Bryn K, Gaudernack G, Myhrvold V, Mørland B. Activation of mononuclear phagocyte functions by structurally different bacterial endotoxins. In: Fossum S, ed. Advances in experimental medicine. Vol 237. Histophysiology of the immune system: The life history, organization, and interactions of its cell populations. New York: Plenum Press, 1989: 793-7.
29. Kelly SE, Hunter JA, Jones DB, Clark BR, Fleming S. Morphological evidence for calcium-dependent association of calgranulin with the epidermal cytoskeleton in inflammatory dermatoses. Br J Dermatol 1991;124:403-9.
30. Bengis-Garber C, Gruener N. Calcium-binding myeloid protein (P8,P14) is phosphorylated in fMet-Leu-Phe-stimulated neutrophils. J Leukocyte Biol 1993;54:114-18.
31. Miyasaki KT, Bodeau AL, Murthy ARK, Lehrer RI. In vitro antimicrobial activity of the human neutrophil cytosolic S-100 protein complex, calprotectin, against Capnocytophaga sputigena. J Dent Res 1993;72:517-23.
32. Lehrer RI. Holocrine secretion of calprotectin: a neutrophilmediated defence against Candida albicans? J Lab Clin Med 1993;121:193-4.
33. Fagerhol MK, Dale I, Anderson I. Release and quantitation of a leucocyte derived protein (L1). Scand J Haematol 1980;24:393-8.
34. Odink K, Cerletti N, Bruggen J, Clerc RG, Tarcsay L, Zwadlo G, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987;330:80-2.
35. Wilson GB, Jahn TL, Fonseca JR. Demonstration of serum protein differences in cystic fibrosis by isoelectic focussing in thin-layer polyacrylamide gels. Clin Chim Acta 1973;49: 79-85.
36. Wilson GB, Fudenberg HH, Jahn TL. Studies on cystic fibrosis using isoelectric focusing. I. An assay for detection of cystic fibrosis homozygotes and heterozygote carriers from serum. Pediatr Res 1975;9:635-40.
37. Dorin JR, Novak M, Hill R, Brock D, Secher D, van Heyningen V. A clue to the basic defect in cystic fibrosis from cloning the CF antigen gene. Nature 1987;326:614-7.
38. Anderson KB, Sletten K, Berntzen HB, Dale I, Brandtzæg P, Jellum E, et al. The leukocyte L1 protein: identity with the cyclic fibrosis antigen and the calcium-binding MRP-8 and MRP-14 macrophage components. Scand J Immunol 1988;28:241-5.
39. Anderson KB, Sletten K. Leukocyte L1 protein and the cystic fibrosis antigen. Nature 1988;332:688.
40. Wilkinson MM, Busuttil A, Hayward C, Brock DJ, Dorin JR, van Heyningen V. Expression pattern of two related cystic fibrosis-associated calcium-binding protein in normal and abnormal tissues. J Cell Sci 1988;91:221-30.
41. Dorin JR, Emslie E, van Heyningen V. Related calcium-binding proteins map to the same subregion of chromosome 1q and to an extended region of synteny on mouse chromosome 3. Genomics 1990;8:420-6.
42. Naess-Andresen CF, Egelandsdal B, Fagerhol MK. Calcium binding and concomitant changes in the structure and heat stability of calprotectin (L1 protein). J Clin Pathol: Mol Pathol 1995;48:M278-84.
43. Raftery MJ, Harrison CA, Jones A, Geczy CL. Isolation of the murine S100 protein MRP 14 (14 kDa migration-inhibitory-factor-related protein) from activated spleen cells: characterization of post-translational modification of zinc binding. Biochem J 1996;316:285-93.
44. Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leucocyte protein, the L1 antigen. Eur J Biochem 1983;134:1-6.
45. Brandtzæg P, Jones DB, Flavell DJ, Fagerhol MK. Mac 387 antibody and detection of formalin resistant myelomonocytic L1 antigen. J Clin Pathol 1988;41:963-70.
46. Kelly SE, Jones DB, Flemming S. Calgranulin expression in inflammatory dermatoses. J Pathol 1989;159:17-21.
47. Guignard F, Mauel J, Marken M. The monoclonal antibody Mac 387 recognizes three S100 proteins in human neutrophils. Immunol Cell Biol 1996;74:105-7.
48. Lagasse E, Clerc RG. Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differenciation. Mol Cell Biol 1988;8:2402-10.
49. Delabie J, DeWolf-Peeters C, van den Oord JJ, Desmet VJ. Differential expression of the calcium-binding proteins MRP8 and MRP14 in granulomatous conditions. An immunohistochemical study. Clin Exp Immunol 1990;81: 123-6.
50. Ivanov GE, Misuno NI, Ivanov VE. Enzyme linked immunosorbent assay for human MRP-8/MRP-14 proteins and their quantitation in plasma of hematological patients. Immunol Let 1996;49:7-13.
51. Johne B. Epitope mapping by surface plasmon resonance in the BIAcore. In: Morris G, ed. Methods in molecular biology. Vol 66. Epitope mapping protocols. Totowa: Humana Press, 1996.
52. Teigelkamp S, Bhardwaj RS, Roth J, Meinardus-Hager G, Karas M, Sorg C. Calcium-dependent complex assembly of the myeloic differentiation proteins MRP-8 and MRP-14. J Biol Chem 1991;266:13462-7.
53. Madsen P, Rasmussen HH, Leffers H, Honoré B, Dejgaard K, Olsen E, et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin. J Invest Dermatol 1991;97:701-12.
54. 2+-binding proteins of neutrophils and monocytes. J Leukocyte Biol 1993;53:197-204.
55. Hessian PA, Wilkinson L, Hogg N. The S100 family protein MRP-14 (S100A9) has homology with the contact domain of high molecular weight kininogen. FEBS Lett 1995;371: 271-5.
56. van Heyningen V, Hayward C, Fletcher J, McAuley C. Tissue localization and chromosomal assignment of a serum protein that tracks the cystic fibrosis gene. Nature 1985;315:513-5.
57. Berntzen HB, Fagerhol MK. L1, a major granulocyte protein: antigenic properties of its subunits. Scand J Clin Lab Invest 1988;48:647-52.
58. Berntzen HB, Fagerhol MK. L1, a major granulocyte protein; isolation of high quantities of its subunits. Scand J Clin Lab Invest 1990;50:769-74.
59. Longbottom D, Sallenave JM, van Heyningen V. Subunit structure of calgranulins A and B obtained from sputum, plasma, granulocytes and cultured epithelial cells. Biochim Biophys Acta 1992;1120:215-22.
60. Brandtzæg P, Dale I, Fagerhol MK. Distribution of a formalin resistant myelomonocytic antigen (L1) in human tissues. 2. Normal and aberrant occurrence in various epithelia. Am J Clin Pathol 1987b;87:700-7.
61. van Heyningen V, Dorin J. Possible role for two calcium-binding proteins of the S-100 family, co-expressed in granulocytes and certain epithelia. Adv Exp Med Biol 1990; 269:139-43.
62. Saintigny G, Schmidt R, Shroot B, Juhlin L, Reichert U, Michel S. Differential expression of calgranulin A and B in various epithelial cell lines and reconstructed epidermis. J Invest Dermatol 1992;99:639-44.
63. Eversole LR, Miyasaki KT, Christensen RE. The distribution of the antimicrobial protein, calprotectin, in normal oral keratinocytes. Arch Oral Biol 1992;37:963-8.
64. Eversole LR, Miyasaki KT, Christensen RE. Keratinocyte expression of calprotectin in oral inflammatory mucosal diseases. J Oral Pathol Med 1993;22:303-7.
65. Coleman N, Stanley MA. Expression of the myelomonocytic antigens CD36 and L1 by keratinocytes in squamous intraepithelial lesions of the cervix. Hum Pathol 1994;25: 73-9.
66. Fanjul M, Renaud W, Merten M, Guycrotte O, Hollande E, Figarella C. Presence of MRP8 and MRP14 in pancreatic cell lines: differential expression and localization in CFPAC-1 cells. Am J Physiol: Cell Physiol 1995;37:C1241-51.
67. Merten MD, Figarella C. Constitutive hypersecretion and insensitivity to neurotransmitters by cystic fibrosis tracheal gland cells. Am J Physiol 1993;264:L93-9.
68. Gabrielsen T-O, Dale I, Brandtzæg P, Hoel PS, Fagerhol MK, Larsen TE, et al. Epidermal and dermal distribution of a myelomonocytic antigen (L1) shared by epithelial cells in various inflammatory skin diseases. J Am Acad Dermatol 1986;15:173-9.
69. Bjerke K, Halstensen TS, Jahnsen F, Pulford, K, Brandtzæg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993;34:1357-63.
70. Nacken W, Manitz MP, Sorg C. Molecular characterisation of the genomic locus of the mouse MRP8 gene. Biochim Biophys Acta 1996;1315:1-5.
71. Naughton PJ, Clohessy PA, Grant G, Pusztai A, Golden B. Faecal calprotectin: non-invasive marker of gastrointestinal inflammation in salmonella infected rats. Biochem Soc Trans 1996;24:308S.
72. Dell'Angelica EC, Schleicher CH, Santome JA. Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J Biol Chem 1994;269:28929-36.
73. Belenko M, Chanana AD, Joel DD, Fagerhol MK, Janoff. Tracing the leukocyte marker protein in lung fluids and lung-draining lymph nodes during endotoxemia in sheep. Am Rev Resp Dis 1986;133:866-74.
74. Yang Z, Deveer MJ, Gardiner EE, Devenish RJ, Handley CJ, Underwood JR, et al. Rabbit polymorphonuclear neutrophils form S-35-labeled S-sulfo-calgranulin C when incubated with inorganic [S-35]sulfate. J Biol Chem 1996; 271:19802-9.
75. Dale I, Brandtzæg P, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L1) in human periferal blood leukocytes. Am J Clin Pathol 1985;84:24-34.
76. Dianoux A-C, Stasia M-J, Garin J, Gagnon J, Vignais PV. The 23-kilodalton protein, a substrate of protein kinase C, in bovine neutrophil cytosol is a member of the S100 family. Biochemistry 1992;31:5898-905.
77. Clark BR, Kelly SE, Flemming S. Calgranulin expression and association with the keratinocyte cytoskeleton. J Pathol 1990;160:25-30.
78. Edgeworth JD, Abiose A, Jones BR. An immunohistochemical analysis of onchocercal nodules: evidence for an interaction between macrophage MRP8/MRP14 and adult Onchocerca volvulus. Clin Exp Immunol 1993;92:84-92.
79. Santhanagopalan V, Hahn BL, Dunn BE, Weissner JH, Sohnle PG. Antimicrobial activity of calprotectin isolated from human empyema fluid supernatants. Clin Immunol Immunopathol 1995;76:285-90.
80. Murthy AR, Lehrer RI, Harwig SS, Miyasaki KT. In vitro candidiastic properties of the human neutrophil calprotectin complex. J Immunol 1993;151:6291-301.
81. Clohessy PA, Golden BF. Calprotectin mediated zinc chelation as a biostatic mechanism in host defence. Scand J Immunol 1995;42:551-6.
82. Clohessy PA, Golden BE. The mechanism of calprotectin's candidastic activity appears to involve zinc chelation. Biochem Soc Trans 1996;24:309S.
83. Kocher M, Kenny PA, Farram E, Majid KBA, Finlayjones JJ, Geczy CL. Functional chemotactic factors CP-10 and MRP-14 are abundant in marine abscesses. Infect Immun 1996;64:1342-50.
84. Zwadlo G, Bruggen J, Gerhards G, Schlegel R, Sorg C. Two calcium-binding proteins associated with specific stages of myeloid cell differentiation are expressed by subsets of macrophages in inflammatory tissues. Clin Exp Immunol 1988;72:510-5.
85. Murao S, Nakanishi M, Matsumoto S, Ueda N, Huberman E. Induction of cell differentiation in human HL-60 promyelocytic leukemia cells: Quantitation of a myeloid specific antigen, MRP-8/MRP-14 protein complex. Cell biology - a laboratory handbook. Vol 1. London: Academic Press, 1994:207-12.
86. Brun JG, Haaland G, Haga HJ, Fagerhol MK, Jonsson R. Effects of calprotectin in avridine-induced arthritis. APMIS 1995;103:233-40.
87. Kligman D, Hilt DC. The S100 protein family. TIBS 1988; 13:437-43.
88. Guignard F, Mauel J, Markert M. Phosphorylation of myeloid-related proteins MRP-14 and MRP-8 during neutrophil activation. Eur J Biochem 1996;241:265-71.
89. Murao S, Collart FR, Huberman E. A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases. J Biol Chem 1989;254:8356-60.
90. Sohnle PG, Collins-Lech C, Wiessner JH. Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils. J Infect Dis 1991;163: 187-92.
91. Brun JG, Cuida M, Jacobsen H, Kloster R, Johannesen AC, Hoyeraal HM, et al. Sjogren's syndrome in inflammatory rheumatic diseases: Analysis of the leukocyte protein calprotectin in plasma and saliva. Scand J Rheumatol 1994; 23:114-18.
92. Levy O. Antibiotic proteins of polymorphonuclear leukocytes. Eur J Haematol 1996;56:263-77.
93. Sohnle P G, Hahn B L, Santanagopalan V. Inhibition of Candida albicans growth by calprotectin in the absence of direct contact with the organisms. J Infect Dis 1996;174: 1369-72.
94. Berntzen HB, Munthe E, Fagerhol MK. A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol 1989;16:1416-20.
95. Olson JA, Forrester M, Clohessy PA, Golden BE, Herriot R, Forrester JV. Calprotectin is raised in endogenousposteriour uveitis. Occular Immunol Inflamm 1996;4:91-8.
96. Haga HJ, Brun JG, Berntzen HB, Cervera R, Khamashta M, Huges GRV. Calprotectin in patients with systemic lupus erythematosus: Relation to clinical and laboratory parameters of disease activity. Lupus 1993;2:47-50.
97. Golden BE, Clohessy PA, Russell G, Fagerhol MK. Calprotectin as a marker of inflammation in cystic fibrosis. Arch Dis Child 1996;74:136-9.
98. Stockley RA, Dale I, Hill SL, Fagerhol MK. Relationship of neutrophil cytoplasmic protein (L1) to acute and chronic lung disease. Scand J Clin Lab Invest 1984;44:629-34.
99. Wick MR, Mills SE, Swanson PE. Expression of "myelomonocytic" antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces. Am J Clin Pathol 1990;94:18-26.
100. Lofthus B, Loh LC, Curran B, Henry K, Leader M. Mac 387: its non-specificity as a tumor marker or marker of histiocytes. Histopathology 1991;19:251-5.
101. Røseth AG, Kristinsson J, Schoønsby H, Nygaard K, Raknerud N, Fagerhol MK, et al. Faecal calprotectin in a consecutive series of outpatients referred tor colonoscopy, with special emphasis on inflammatory bowel disease and colorectal neoplasia. Digestion. [In press.]
102. Gilbert JA, Ahlquist AA, Mahoney DW, Zinsmeister AR, Rubin J, Ellefson RD. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin. Scand J Gastroenterol 1996;31:1001-5.
103. 2+-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn's disease. Digestion 1995;56:406-14.
104. Schmid KW, Lugering N, Stoll R, Brinkbaumer P, Winde G, Damschke W, et at. Immunohistochemical demonstration of the calcium-binding proteins MRP8 and MRP14 and their heterodimer (27E10 antigen) in Crohn's disease. Hum Pathol 1995;26:334-7.
105. Røseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
106. Lügering N, Stoll R, Schmid KW, Kucharzik T, Stein H, Burmeister G. The myeloic related protein MRP8/14 (27E10 antigen) usefulness as a potential marker for discase cativity in ulcerative colitis and putative biological function. Eur J Clin Invest 1995;25:659-64.
107. Foster R, Bjarnason IB, Roseth AG, Fagerhol MK, Peters TJ. Alcohol misuse causes a reversible inflammatory enteropathy with increased intestinal permeability. Alcohol Alcoholism 1995;30:C5.2.
108. Meling T, Aabakken L, Røseth A, Osnes M. Faecal calprotectin-shedding after short term treatment with non-steroidal anti inflammatory drugs. Scand J Gastroenterol 1996;31:339-44.
109. Umekawa T, Kurite T. Calprotectin-like protein is related to soluble organic matrix in calcium oxalate urinary stone. Biochem. Mol Biol Int 1994;34:309-13.
110. Ulvestad E, Williams K, Mork S, Antel J, Nyland H. Phenotypic differences between human monocytes/ macrophages and microglial cells studied in situ and in vitro. J Neuropathol Exp Neurol 1994;53:492-501.
111. Müller F, Frøland SS, Brandtzæg P, Fagerhol MK. Oral candidiasis is associated with low levels of parotid calprotectin in individuals with infection due to human immunodeficiency virus. Clin Inject Dis 1993;16:301-2.
112. Arvesen K, Kontny F, Toss H, Wallentin L, Røseth A, Sundset A, et al. Calprotectin: a novel plasma marker of granulocyte activation in acute coronary syndrome [abstract]. Eur Heart J 1996;17:429.
113. Dale I. Plasma levels of the calcium-binding L1 leukocyte protein: standardization of blood collection and evaluation of reference intervals in healthy controls. Scand J Clin Lab Invest 1990;50:837-41.
114. Semb AG, Gabrielsen TO, Halstensen TS, Fagerhol MK, Brandtzæg P, Vaage J. Cardiac surgery and distribution of the leukocyte L1 protein - calprotectin. J Cardiothorac Surg 1991;5:363-7.
115. Garred P, Fosse E, Fagerhol MK, Videm V, Mollnes TE. Calprotectin and complement activation during major operations with or without cardiopulmonary bypass. Ann Thorac Surg 1993;55:694-9.
116. Fosse E, Moen O, Johnson F, Semb G, Brockmeier V, Mollnes TE, et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994;58:472-7.
117. Hetland G, Berntzen HB, Fagerhoel MK. Levels of calprotectin (leukocyte L1 protein) during apheresis. Scand J Clin Lab Invest 1992;52:479-82.
118. Lügering N, Stoll R, Kucharsik T, Burmeister G, Sorg C, Domschke W. Serum 27E10 antigen: a new potential marker for staging HIV disease. Clin Exp Immunol 1995;101:249-53.
119. Müller F, Frøland S, Aukrust P, Fagerhol MK. Elevated serum calprotectin levels in HIV-infected patients: the calprotectin response during ZDV treatment is associated with clinical events. J Acq Immun Defic Syndr 1994;7:931-9.
120. Holt J, Fagerhol MK, Dale I. Quantitation of a leukocyte protein (L1) in urine. Acta Paediatr Scand 1983;72:615-16.
121. Cuida M, Brun JG, Tynning T, Jonsson R. Calprotectin levels in oral fluids: the importance of collection site. Eur J Oral Sci 1995;103:8-10.
122. Sohnle PG, Collins-Lech C, Wiessner JH. The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. J Infect Dis 1991;164:137-42.
123. Fagerhol MK, Dale I, Boye N, Fjeld N, Urianstad M. Plasma L1 protein levels: a marker for early pulmonary cancer [abstract]. Clin Res 1985;33:617A.
124. Waage A, Brandtzæg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989;169: 333-8.
125. Hjortdal P, Landaas S, Urdal P, Steinbakk M, Fuglerud P, Nygaard B. C-reactive protein: a new rapid assay for managing infectious disease in primary health care. J Prim Health Care 1991;3:3-10.
126. Hu S-P, Harrison C, Xu K, Cornish CJ, Geczy CL. Induction of the chemotactic S100 protein, CP-10, in monocyte/ macrophages by lipopolysaccharide. Blood 1996;87:3919-28.
127. Homann C, Garred P, Graudal N, Hasselquist P, Christiansen M, Fagerhol MK, et al. Plasma calprotectin: A new prognostic marker of survival in alchohol-induced cirrosis. Hepatology 1995;21:979-85.
128. Pekna M, Borowiec J, Fagerhol MK, Venge P, Thelin S. Biocompatibility of heparin-coated curcuits used in cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1994; 28:5-11.
129. Moen O, Fosse E, Bråten J, Andersson C, Fagerhol MK, Høgåsen K, et al. Roller and centrifugal pumps compared in vitro with regard to haemolysis, granulocyte and complement activation. Perfusion 1994;9:109-17.
130. Shute J, Fagerhol MK, Parmar J, Holgate S, Howarth P. Calprotectin, a urinary marker of disease activity in severe asthma [abstract]. BALR Summer Meeting 1996.
131. Svennevig J-L, Lunde OC, Holter J. In situ analysis of the inflammatory cell infiltrates in colon carcinomas and in the normal colon wall. Acta Path Microbiol Immunol Scand 1982;90:131-7.
132. Johne B, Hansen K, Mørk E, Holtlund J. Colloidal gold conjugated monoclonal antibodies, studied in the BIAcore biosensor and in the NycoCard immunoassay format. J Immunol Methods 1995;183:167-74.
133. Rugtveit J, Scott H, Halstensen TS, Norstein J, Brandtzæg P. Expression of the L1 antigen (calprotectin) by tissue macrophages reflects recent recruitment from peripheral blood rather than upregulation of local synthesis: Implications for rejection diagnosis in formalin-fixed kidney specimens. J Pathol 1996;180:194-9.
134. Prydz H, Allison AC. Tissue thromboplastin activity of isolated human monocytes. Thrombos Haemostas 1978;39; 582-91.
135. Prydz H, Lyberg T, Deteix P, Allison AC. In vitro stimulation of tissue thromboplastin (factor III) activity in human monocytes by immune complexes and lectins. Thromb Res 1979;15:465-74.
136. Yam LT, Li CY, Crosby WH. Cytochemical identification of monocytes and granulocytes. Am J Clin Path 1971;55: 283-90.
137. Kirkeby K, Prydz H. Lactic dehydrogenase activity in pleural and peritoneal effusions. Scand J Clin Lab Invest 1959;11:185-9.
138. Gordon S, Todd J, Cohn ZA. In vitro synthesis of lysozyme by mononuclear phagocytes. J Exp Med 1974;139:1228-48.
139. Gianetto R, deDuve C. Tissue fractionation studies. 4. Comparative study of the binding of acid phosphatase, beta-glucoronidase and cathepsin by rat liver particles. Biochem J 1955;59:433-8.
140. Prydz H, Lyberg T. Effect of some drugs on thromboplastin (factor III) activity of human monocytes in vitro. Biochem Pharm 1980;29:9-14.
141. van Calker D, Mhller M, Hamprecht B. Indomethacin in submicromolar concentrations inhibits cyclic AMP-dependent protein kinase. Nature 1978;276:841-2.
142. Roth J, Goebler M, Wrocklage V, Bos C, Sorg C. Expression of the calcium binding proteins MRP8 and MRP14 in monocytes is regulated by a calcium-induced suppressor mechanism. Biochem J 1994;301:655-60.